Metformin disrupts malignant behavior of oral squamous cell carcinoma via a novel signaling involving Late SV40 factor/Aurora-A

Chang Han Chen; Hsin Ting Tsai; Hui Ching Chuang; Li Yen Shiu; Li Jen Su; Tai Jan Chiu; Sheng Dean Luo; Fu Min Fang; Chao Cheng Huang; Chih Yen Chien

doi:10.1038/s41598-017-01353-8

Metformin disrupts malignant behavior of oral squamous cell carcinoma via a novel signaling involving Late SV40 factor/Aurora-A

Chang Han Chen, Hsin Ting Tsai, Hui Ching Chuang, Li Yen Shiu, Li Jen Su, Tai Jan Chiu, Sheng Dean Luo, Fu Min Fang, Chao Cheng Huang, Chih Yen Chien

Department of Biomedical Sciences and Engineering

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Conventional therapeutic processes in patient with OSCC are associated with several unfavorable effects leading to patients with poor survival rate. Metformin has been shown to protect against a variety of specific diseases, including cancer. However, the precise roles and mechanisms underlying the therapeutic effects of metformin on OSCC remain elusive. In the current study, in vitro and xenograft model experiments revealed that metformin inhibited growth and metastasis of oral cancer cells. Importantly, metformin-restrained tumorigenesis of oral cancer was accompanied with strong decrease of both Aurora-A and Late SV40 Factor (LSF) expressions. Furthermore, LSF contributed to Aurora-A-elicited malignancy behaviors of oral cancer via binding to the promoter region of Aurora-A. A significant correlation was observed between LSF and Aurora-A levels in a cohort of specimens of oral cancer. These findings showed that a novel LSF/Aurora-A-signaling inhibition supports the rationale of using metformin as potential OSCC therapeutics.

Original language	English
Article number	1358
Journal	Scientific Reports
Volume	7
Issue number	1
DOIs	https://doi.org/10.1038/s41598-017-01353-8
State	Published - 1 Dec 2017

Access to Document

10.1038/s41598-017-01353-8

Cite this

@article{5c0ca8d33e754e73a7ca60fe8ab8ee48,

title = "Metformin disrupts malignant behavior of oral squamous cell carcinoma via a novel signaling involving Late SV40 factor/Aurora-A",

abstract = "Conventional therapeutic processes in patient with OSCC are associated with several unfavorable effects leading to patients with poor survival rate. Metformin has been shown to protect against a variety of specific diseases, including cancer. However, the precise roles and mechanisms underlying the therapeutic effects of metformin on OSCC remain elusive. In the current study, in vitro and xenograft model experiments revealed that metformin inhibited growth and metastasis of oral cancer cells. Importantly, metformin-restrained tumorigenesis of oral cancer was accompanied with strong decrease of both Aurora-A and Late SV40 Factor (LSF) expressions. Furthermore, LSF contributed to Aurora-A-elicited malignancy behaviors of oral cancer via binding to the promoter region of Aurora-A. A significant correlation was observed between LSF and Aurora-A levels in a cohort of specimens of oral cancer. These findings showed that a novel LSF/Aurora-A-signaling inhibition supports the rationale of using metformin as potential OSCC therapeutics.",

author = "Chen, {Chang Han} and Tsai, {Hsin Ting} and Chuang, {Hui Ching} and Shiu, {Li Yen} and Su, {Li Jen} and Chiu, {Tai Jan} and Luo, {Sheng Dean} and Fang, {Fu Min} and Huang, {Chao Cheng} and Chien, {Chih Yen}",

note = "Publisher Copyright: {\textcopyright} 2017 The Author(s).",

year = "2017",

month = dec,

day = "1",

doi = "10.1038/s41598-017-01353-8",

language = "???core.languages.en_GB???",

volume = "7",

journal = "Scientific Reports",

issn = "2045-2322",

number = "1",

}

TY - JOUR

T1 - Metformin disrupts malignant behavior of oral squamous cell carcinoma via a novel signaling involving Late SV40 factor/Aurora-A

AU - Chen, Chang Han

AU - Tsai, Hsin Ting

AU - Chuang, Hui Ching

AU - Shiu, Li Yen

AU - Su, Li Jen

AU - Chiu, Tai Jan

AU - Luo, Sheng Dean

AU - Fang, Fu Min

AU - Huang, Chao Cheng

AU - Chien, Chih Yen

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Conventional therapeutic processes in patient with OSCC are associated with several unfavorable effects leading to patients with poor survival rate. Metformin has been shown to protect against a variety of specific diseases, including cancer. However, the precise roles and mechanisms underlying the therapeutic effects of metformin on OSCC remain elusive. In the current study, in vitro and xenograft model experiments revealed that metformin inhibited growth and metastasis of oral cancer cells. Importantly, metformin-restrained tumorigenesis of oral cancer was accompanied with strong decrease of both Aurora-A and Late SV40 Factor (LSF) expressions. Furthermore, LSF contributed to Aurora-A-elicited malignancy behaviors of oral cancer via binding to the promoter region of Aurora-A. A significant correlation was observed between LSF and Aurora-A levels in a cohort of specimens of oral cancer. These findings showed that a novel LSF/Aurora-A-signaling inhibition supports the rationale of using metformin as potential OSCC therapeutics.

AB - Conventional therapeutic processes in patient with OSCC are associated with several unfavorable effects leading to patients with poor survival rate. Metformin has been shown to protect against a variety of specific diseases, including cancer. However, the precise roles and mechanisms underlying the therapeutic effects of metformin on OSCC remain elusive. In the current study, in vitro and xenograft model experiments revealed that metformin inhibited growth and metastasis of oral cancer cells. Importantly, metformin-restrained tumorigenesis of oral cancer was accompanied with strong decrease of both Aurora-A and Late SV40 Factor (LSF) expressions. Furthermore, LSF contributed to Aurora-A-elicited malignancy behaviors of oral cancer via binding to the promoter region of Aurora-A. A significant correlation was observed between LSF and Aurora-A levels in a cohort of specimens of oral cancer. These findings showed that a novel LSF/Aurora-A-signaling inhibition supports the rationale of using metformin as potential OSCC therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=85018271835&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-01353-8

DO - 10.1038/s41598-017-01353-8

M3 - 期刊論文

C2 - 28465536

AN - SCOPUS:85018271835

SN - 2045-2322

VL - 7

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 1358

ER -

Metformin disrupts malignant behavior of oral squamous cell carcinoma via a novel signaling involving Late SV40 factor/Aurora-A

Abstract

Access to Document

Fingerprint

Cite this